Wegener’s granulomatosis: Is biologic therapy useful?

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Current Rheumatology Reports

• Publication date

  2006-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/S11926-006-0014-6PMID 16839510
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.

  2006cited by this paper
• Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies.

  2006cited by this paper
• WEGENER’S AUTOANTIGEN INDUCES MATURATION OF DENDRITIC CELLS AND LICENCES THEM FOR TH1 PRIMING VIA THE PROTEASE-ACTIVATED RECEPTOR-2 PATHWAY Running head: Maturation of dendritic cells by proteinase 3

  2006cited by this paper
• Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway.

  2006cited by this paper
• Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial.

  2006cited by this paper
• B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis.

  2005cited by this paper
• Differentiating the efficacy of the tumor necrosis factor inhibitors.

  2005cited by this paper
• Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.

  2005cited by this paper
• CD20: a target antigen for immunotherapy of autoimmune diseases.

  2005cited by this paper
• Nine patients with anti‐neutrophil cytoplasmic antibody‐positive vasculitis successfully treated with rituximab

  2005cited by this paper
• Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations

  2005cited by this paper
• Differentiating the efficacy of tumor necrosis factor inhibitors.

  2005cited by this paper
• Wegener's granulomatosis: a view from the granulomatous side of the disease.

  2005cited by this paper
• Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).

  2005cited by this paper
• Rituximab and Wegener's granulomatosis: are B cells a target in vasculitis treatment?

  2005cited by this paper
• Distinct mechanisms of action of tumor necrosis factor antagonists: what are the clinical implications?

  2005cited by this paper
• Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.

  2005cited by this paper
• Pathogenesis of Wegener's granulomatosis: current concepts

  2005cited by this paper
• Etanercept plus Standard Therapy for Wegener's Granulomatosis

  2005cited by this paper
• Etanercept plus standard therapy for Wegener's granulomatosis.

  2005cited by this paper
• Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

  2004cited by this paper
• Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: an investigation in 24,831 patients.

  2004cited by this paper
• Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo.

  2004cited by this paper
• Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis.

  2004cited by this paper
• B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.

  2004cited by this paper
• Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis.

  2004cited by this paper
• Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse.

  2003cited by this paper
• Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.

  2003cited by this paper
• Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis.

  2003cited by this paper
• Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

  2003cited by this paper
• Maintenance of remission with leflunomide in Wegener's granulomatosis.

  2003cited by this paper
• A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.

  2003influential reference
• Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis.

  2002cited by this paper
• Granuloma formation, implications for the pathogenesis of vasculitis.

  2002cited by this paper
• Peripheral Blood and Granuloma CD4+CD28− T Cells Are a Major Source of Interferon-γ and Tumor Necrosis Factor-α in Wegener’s Granulomatosis

  2002cited by this paper
• Cancer incidence in a population‐based cohort of patients with Wegener's granulomatosis

  2002cited by this paper
• Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells.

  2002cited by this paper
• Safety and efficacy of TNFalpha blockade in relapsing vasculitis.

  2002cited by this paper
• Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener's granulomatosis.

  2002cited by this paper
• Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice.

  2002cited by this paper
• Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients.

  2002cited by this paper
• Elevated monocytic IL‐12 and TNF‐α production in Wegener’s granulomatosis is normalized by cyclophosphamide and corticosteroid therapy

  2002cited by this paper
• Safety and efficacy of TNF a blockade in relapsing vasculitis

  2002cited by this paper
• Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s.

  2002influential reference
• CD28 negative T cells are enriched in granulomatous lesions of the respiratory tract in Wegener's granulomatosis

  2001cited by this paper
• Increased expression of CTLA‐4 (CD152) by T and B lymphocytes in Wegener's granulomatosis

  2001cited by this paper
• Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

  2001cited by this paper
• Update on the diagnosis and treatment of Wegener's granulomatosis.

  2001cited by this paper
• Anca associated vasculitis: occurrence, prediction, prevention, and outcome of relapses

  2001cited by this paper
• Bronchoalveolar lavage cell profiles in Wegener's granulomatosis.

  1999cited by this paper
• A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance.

  1999cited by this paper
• Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10.

  1998cited by this paper
• Orbital involvement in Wegener granulomatosis: MR findings in 12 patients.

  1997cited by this paper
• Cyclophosphamide-Induced Cystitis and Bladder Cancer in Patients with Wegener Granulomatosis

  1996cited by this paper
• Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis.

  1996cited by this paper
• An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone.

  1995cited by this paper
• "Wegener's granulomatosis": the path traveled since 1931.

  1994cited by this paper
• In situ production of TNF-α, IL-1β and IL-2R in ANCA-positive glomerulonephritis

  1993cited by this paper
• Limited prognostic value of changes in antineutrophil cytoplasmic antibody titers in patients with Wegener's granulomatosis.

  1993cited by this paper
• Value of tests for antineutrophil cytoplasmic autoantibodies in the diagnosis and treatment of vasculitis.

  1993cited by this paper
• In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis.

  1993cited by this paper
• Wegener Granulomatosis: An Analysis of 158 Patients

  1992cited by this paper
• Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro.

  1990cited by this paper
• WEGENER'S GRANULOMATOSIS: STUDIES IN EIGHTEEN PATIENTS AND A REVIEW OF THE LITERATURE

  1973cited by this paper
• The use of alkylating agents in the treatment of Wegener's granulomatosis.

  1967cited by this paper
• Giant-cell Granuloma of the Respiratory Tract (Wegener's Granulomatosis)

  1958cited by this paper
• Wegener's granulomatosis.

  1954cited by this paper

• Clinicopathological Profile of Tuberculosis and Non-Tuberculosis Chronic Granulomatous Lymphadenitis at the Department of Anatomic Pathology, Faculty of Medicine, University of Indonesia/Dr. Cipto Mangunkusumo Hospital from 2018 to 2022

  2025influential citation
• From inflammatory bowel disease to colorectal cancer: what’s the role of miRNAs?

  2022cites this paper
• Noninfectious Granulomatous Diseases of the Chest.

  2020cites this paper
• Effect of radiotherapy in a patient with Wegener’s granulomatosis – case report

  2009cites this paper
• Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease.

  2009cites this paper
• Respiratory Disease Antibody-Associated Vasculitides and Antineutrophil Cytoplasmic

  2009cites this paper
• Efekt radioterapii u chorego na ziarniniaka Wegenera - opis przypadku Effect of radiotherapy in a patient with Wegener's granulomatosis - case report

  2008cites this paper
• Immunotherapy for antineutrophil cytoplasmic antibody-associated vasculitis: challenging the therapeutic status quo?

  2008cites this paper
• Targeted Biologic Approaches to the Treatment of Systemic Vasculitis

  2008cites this paper
• Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review.

  2007cites this paper